Milestone Pharmaceuticals to Present Etripamil Data at ESC Congress 2024

MONTREAL and CHARLOTTE, N.C., Aug. 26, 2024 – Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical firm specializing in innovative cardiovascular treatments, announced a significant upcoming data presentation on their investigational drug etripamil. This presentation will occur at the annual European Society of Cardiology (ESC) Congress 2024 in London, United Kingdom, on August 30, 2024. 

The presentation, led by Professor John Camm from St. George's University of London, will focus on patient-reported outcomes from the NODE-303 Phase 3 trial of etripamil. This trial investigates the drug's efficacy in treating paroxysmal supraventricular tachycardia (PSVT) in settings where medical supervision is not immediately available. The findings will be shared during a moderated poster presentation.

Dr. David Bharucha, Chief Medical Officer at Milestone Pharmaceuticals, expressed anticipation for the presentation, emphasizing the importance of PSVT and the self-administration of etripamil nasal spray. He highlighted that the forthcoming patient-reported outcomes data would shed light on patient experiences, satisfaction, and management of the condition.

Key details of the ESC presentation are as follows:
- Title: Quality of Life Measures with Etripamil Self-Administration for Acute Episodes of Paroxysmal Supraventricular Tachycardia in a Medically Unsupervised Setting: Patient-Reported Outcomes from NODE-303
- Presenter: John Camm, MD, Professor of Clinical Cardiology, St. George's University of London
- Date and Time: Friday, August 30, 2024, 13:00 – 13:50 BST

Milestone Pharmaceuticals is dedicated to addressing unmet patient needs and enhancing the patient experience through innovative cardiovascular treatments. Their lead product, etripamil, is a novel calcium channel blocker formulated as a nasal spray. This drug is designed to be self-administered by patients without the need for medical supervision during symptomatic attacks associated with PSVT and AFib-RVR.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!